New research shows that type 2 diabetes (T2D) is linked to an imbalance in the gut microbiome. Over time, people with T2D have lost beneficial bacterial strains that help digest dietary fiber and produce butyrate, a key molecule needed for balancing insulin and glucose levels. Research shows there are three components to managing diabetes: diet, exercise and the microbiome. This helps explain why diet and exercise are often not enough to keep blood glucose under control. [1-3, 36] The connection between the gut microbiome and T2D has been widely recognized by the American Diabetes Association, Mayo Clinic, Johns Hopkins and others. [13-15]
This observed reduction in glucose AUC would be expected to increase the time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring. Increases in TIR70-180 strongly correlate to both reductions in A1c and reduction in risk for complications in T2D patients
Pendulum Glucose Control (PGC) is a synbiotic that contains targeted strains of probiotics (beneficial bacteria) and a prebiotic (food to fuel bacteria) for the dietary management of type 2 diabetes. It is clinically shown to help people with T2D taking metformin manage A1C and blood glucose spikes.
Clinically Tested. PGC has been clinically shown to help people with type 2 diabetes (T2D) taking metformin manage A1C and blood sugar spikes. These results were presented at the American Diabetes Association's 79th Scientific Sessions.
Novel and Targeted. Our unique, patented formula includes targeted strains discovered through DNA sequencing to meet the specific dietary needs of people with T2D. Pendulum Glucose Control is designed to address deficiencies and increase the gut microbiome's butyrate-producing and mucin-regulating functions.
This observed reduction in glucose AUC would be expected to increase the time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring. Increases in TIR70-180 strongly correlate to both reductions in A1c and reduction in risk for complications in T2D patients
In a randomized, double-blinded, placebo controlled, multi-site study, PGC demonstrated statistically significant reductions in A1C and blood sugar spikes (AUC), after 12 weeks of use, compared to placebo, in people with T2D, managed with diet and exercise alone, or, in combination with metformin and/or sulfonylurea.
“We found Pendulum Glucose Control to be safe, well-tolerated, and an effective way to help those living with type 2 diabetes manage their disease,” says Dr. Damaris Vega, endocrinologist, Juno Research LLC.
To review the full study, click here.
*A nutrition study demonstrated significant reduction in A1C and blood glucose spikes in people with type 2 diabetes taking metformin after 12 weeks of use and compared to placebo.
It was randomized, double-blinded, placebo controlled, and across multiple sites in the U.S.
This observed reduction in glucose AUC would be expected to increase the time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring. Increases in TIR70-180 strongly correlate to both reductions in A1c and reduction in risk for complications in T2D patients (see details here)
We've partnered with leading researchers at the Mayo Clinic to create the first Mayo Registry for a medical probiotic. The Mayo Clinic has been a leader in advancing microbiome science through the Mayo Microbiome Program. The Mayo Clinic is compiling and reporting results from PGC customers who voluntarily and anonymously share their data. All PGC customers are eligible to participate in this important scientific endeavor.
This observed reduction in glucose AUC would be expected to increase the time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring. Increases in TIR70-180 strongly correlate to both reductions in A1c and reduction in risk for complications in T2D patients
PGC delivers targeted beneficial bacterial strains to the gut microbiome for people with T2D to help restore lost functionality of metabolizing fiber into butyrate.
Butyrate is a short chain fatty acid critical to digestive health, a healthy metabolism and healthy blood glucose levels. Over 5,000 research studies have shown that butyrate plays several important roles in the gut. It’s a major fuel source for cells lining the large intestine and is involved in improving immunity and reducing inflammation. Butyrate also plays a role in stimulating GLP-1 (a hormone produced by the gut) secretion, which helps maintain a healthy balance between insulin and glucose levels. [5, 6,8, 9, 24-30]
*Figure adapted from "Alterations in Gut Microbiota and Immunity by Dietary Fat,"
Yonsei Medical Journal 58(6):1083, November 2017.
https://www.researchgate.net/publication/320492093_Alterations_in_Gut_Microbiota_and_Immunity_by_Dietary_Fat
This observed reduction in glucose AUC would be expected to increase the time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring. Increases in TIR70-180 strongly correlate to both reductions in A1c and reduction in risk for complications in T2D patients
Butyrate signals to the immune system when immune defenses need to ramp up. When there is not enough butyrate production in the microbiome, the immune system is compromised.
Mucin protects your gut lining (and ultimately the immune system). PGC contains novel strain Akkermansia muciniphila, which has been shown in 3rd party research to help modulate the gut lining. People with type 2 diabetes are shown to have lower levels of Akkermansia and gut lining modulation. A strong gut lining is vital to ensure that small molecules in the gut don't “leak” across the gut lining into the bloodstream, which can cause heightened inflammation and compromise the immune system. [33-34]
This observed reduction in glucose AUC would be expected to increase the time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring. Increases in TIR70-180 strongly correlate to both reductions in A1c and reduction in risk for complications in T2D patients
Our medical research team is led by Chief Medical Officer, Orville Kolterman, M.D. Dr. Kolterman is a well-respected diabetes expert, based on his contributions to diabetes drug development and the diabetes community. He was previously the Chief Medical Officer at Amylin Pharmaceuticals, where he brought four diabetes drugs from early-stage development through trials and to market.
Together with Dr. Kolterman, we work with leading diabetes professionals to ensure that our products deliver exceptional results and meet the highest standards of efficacy and safety.
Dr. Kolterman received his MD from Stanford University School of Medicine, performed his residency in Internal Medicine at the University of Chicago and Endocrinology training at Stanford.
This observed reduction in glucose AUC would be expected to increase the time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring. Increases in TIR70-180 strongly correlate to both reductions in A1c and reduction in risk for complications in T2D patients
